

ASX ANNOUNCEMENT

31 AUGUST 2016

Company Secretary Appointment

MELBOURNE, AUSTRALIA: Cognitive science company, Cogstate (ASX.CGS), is pleased to announce the appointment of Cindy Tilley as acting Company Secretary.

Cindy recently joined Cogstate to replace Abby Moore as acting Finance Manager and Company Secretary, while Claire Newstead-Sinclair is on maternity leave.

Cindy completed a Bachelor of Commerce at the Australian National University and is a member of Certified Practising Accountants (CPA) Australia and the Australian Institute of Company Directors (AICD). Cindy has over 16 years' experience in finance and accounting, having commenced her career as an undergraduate in business services before joining Lend Lease where she held various senior finance roles spanning 15 years and most recently as Group Financial Controller and Company Secretary for Probuild.

ABOUT COGSTATE

Cogstate Ltd (ASX:CGS) is a leading cognitive science company delivering software and services to optimise the measurement of cognition in clinical trials, academic research, healthcare and brain injury. Cogstate is a pioneer in commercialising rapid, reliable and highly sensitive computerised cognitive tests and provides expert support for traditional neurological assessments to drive higher quality outcome measures. Cogstate clients include the world's leading biopharmaceutical companies; military and elite sporting organisations; physicians and patients; renowned academic institutions and public-private partnerships. With more than 130 employees and a global network of expert neuropsychologist consultants across 25 countries, the unique intersection of science, innovation and delivery is at the core of everything we do.

In our Clinical Trials business, Cogstate provides both software and professional services for clinical research programs seeking to demonstrate a drug's impact on cognition. Our latest innovation, Precision Recruitment™, is an online pre-screening portal that accelerates the identification of qualified clinical trial participants in high-need indications such as Alzheimer's disease.

For further information contact:

Brad O'Connor
Cogstate Chief Executive Officer
+613 9664 1300 or 0411 888 347
boconnor@cogstate.com

Kyahn Williamson
Buchan Consulting
0401 018 828
kwilliamson@buchanwe.com.au